Law360, New York (July 6, 2005, 12:00 AM EDT) -- Israeli drug maker Teva Pharmaceutical Industries Ltd. said Wednesday it would sue the U.S. Food and Drug Administration over a decision that effectively wiped out the company’s marketing exclusivity for a generic version of Bristol-Myers Squibb Co.'s cholesterol medication Pravachol.
Teva said it strongly disagreed with the FDA ruling, which determined that the 180-day exclusivity period for generic versions Pravachol began on August 22, when another generic drug maker's lawsuit against Bristol-Myers was dismissed.
In that case, Canadian drug maker Apotex Inc. had sought a declaratory...
Teva To Sue FDA Over Pravachol Marketing Exclusivity
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
